Press Releases

• Acumen Pharmaceuticals: Presents Studies on Enhanced Brain Delivery, Biomarker Research, and Novel Antibodies at Advances in Alzheimer's Treatment at International Conference on Alzheimer’s and Parkinson’s Diseases 2026 More
• Alloy Therapeutics: Enters Into Agreement to Advance Novel Antibody Discovery Platform More
• Asimov: Cell Line Development Partnership With Score Pharma to Advance Biosuperior Antibody Therapeutics More
• Candel Therapeutics: Extended Survival Tail Observed in Trial of Aglatimagene Besadenovec (CAN-2409) in Advanced Non-Small Cell Lung Cancer Patients With Inadequate Response to Immune Checkpoint Inhibitors More
• Cellino: Appoints Ed Tekeian as Chief Operating Officer More
• Cognito Therapeutics: Presents New Data on Spectris in Alzheimer’s Disease at AD/PD 2026 More
• iSpecimen: Achieves Rapid Procurement Milestone for Influenza Research More
• Manifold Bio: Demonstrates Million-Scale Experimental Validation of AI-Driven Protein Binder Design With NVIDIA More
• NeuroSense Therapeutics: JAMA Neurology Publishes Results From PARADIGM Phase 2b Trial of PrimeC in ALS Demonstrating Meaningful Clinical Outcomes and Biological Activity More
• Rhythm Pharmaceuticals: Topline Results From Phase 3 EMANATE Trial More

Financial News

• Acumen Pharmaceuticals: $35.75 Million Private Placement to Advance Potential Best-in-Class Molecules From Amyloid Beta Oligomer-Selective Enhanced Brain Delivery Portfolio More
• Bicycle Therapeutics: Recent Business Progress and Fourth Quarter and Full Year 2025 Financial Results More
• Black Diamond Therapeutics: Fourth Quarter and Full Year 2025 Financial Results and Corporate Update More
• CervoMed: Fourth Quarter and Full Year 2025 Financial Results and Provides Corporate Updates More
• Cue Biopharma: Fourth Quarter and Full Year 2025 Financial Results and Business Highlights More
• Elicio Therapeutics: Inducement Grants More
• Monte Rosa Therapeutics: Fourth Quarter and Full-Year 2025 Financial Results and Business Updates More
• Sensei Biotherapeutics: Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) More
• Vicarious Surgical: Strategic Plan to Pursue Nasdaq Listing More
• Zenas BioPharma: Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) More
  

Media/Misc Coverage

• More on Sarepta Testing New Elevidys Safeguards More
• Polygenic Risk Score Better Predicts Obesity and Diabetes Across Ancestries More
  
• Subscribe to LifeSci Startup for Updates on US Startups More

Career Center

• AI in Biotech: The New Frontier for Leadership & Strategy More
• Flagship Startup Loses CEO to Ipsen; Ionis to Shed Nearly Six Decades of Board Experience More*
  
• From Seed to Series C: What Investors Look for Beyond the Science More
• ICYMI: CEO’s Perspective: Big Moves Come with Big Responsibility More
• ICYMI: CEO’s Perspective: The High Cost of Job Hopping More
• ICYMI: Elevating Executive Presence: A Blueprint for Life Sciences and Biotech Leaders More
• M&A in Life Sciences: The Turning Tide – Why Now is a Strategic Inflection for Biopharma and Biotech More
• 6 Companies Hiring in Cambridge More
• The Rise of Fractional Talent in Life Sciences: What to Expect in 2026 More

• PAP – Patient Assistance & Access Programs March 17-18
• Rare Disease Summit March 17-19
• Hub and Specialty Pharmacy Models East March 17-19
• Charles River QC Micro Summit March 17-19
• New Jersey Inaugural Symposium for Life Science Innovation and Development March 23
• Life Sciences Accounting & Reporting Congress 2026 March 23-25
• Patients as Partners in Clinical Research March 24-26
• Charles River Cell & Gene Therapy Summit March 26 
• CMO Summit 360° April 13-14
• Drug Discovery Chemistry April 13-16
• Delaware’s DNA | 2026 Life Science Conference April 30
• Bio-IT World Conference & Expo May 19-21

Companies

Boston Sponsors